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Pain and Physical and Psychological Symptoms in Ambulatory HIV
Patients in the Current Treatment Era
Abstract
Context
HIV infection has become a manageable chronic disease. There are few studies of pain and symptoms in the
current treatment era.
Objectives
The primary objective was to determine the prevalence of and risk factors for pain and physical and
psychological symptoms in a population of ambulatory HIV patients.
Methods
We performed a cross-sectional study using the Brief Pain Inventory and the Memorial Symptom Assessment
Scale.
Results
We evaluated 156 individuals with a median age of 47.5 years (range 21–71), median time since HIV
diagnosis of 11 years (range 3(interquartile range [IQR] 308–683). The majority (125, 80.6%) had an
undetectable viral load. Seventy-six (48.7%) reported pain, of whom 39 (51.3%) had moderate to severe pain,
and 43 (57.3%) had pain that caused moderate to severe interference with their lives. The median number of
symptoms was eight (IQR 5–14.5) of 32 queried. In multivariable analyses, patients with psychiatric illness
were 39.8% more likely to have pain (P
Conclusion
Pain and other physical and psychological symptoms were common among ambulatory HIV patients. Pain
and symptoms were strongly associated with psychiatric illness and IV drug use. Future investigation should
evaluate interventions that include psychiatric and substance abuse components for HIV patients with pain.
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Abstract
Context—HIV infection has become a manageable chronic disease. There are few studies of pain
and symptoms in the current treatment era.
Objectives—The primary objective was to determine the prevalence of and risk factors for pain
and physical and psychological symptoms in a population of ambulatory HIV patients.
Methods—We performed a cross-sectional study using the Brief Pain Inventory and the
Memorial Symptom Assessment Scale.
Results—We evaluated 156 individuals with a median age of 47.5 years (range 21–71), median
time since HIV diagnosis of 11 years (range <1–25), and median CD4+ cell count of 502 cells/
mm3 (interquartile range [IQR] 308–683). The majority (125, 80.6%) had an undetectable viral
load. Seventy-six (48.7%) reported pain, of whom 39 (51.3%) had moderate to severe pain, and 43
(57.3%) had pain that caused moderate to severe interference with their lives. The median number
of symptoms was eight (IQR 5–14.5) of 32 queried. In multivariable analyses, patients with
psychiatric illness were 39.8% more likely to have pain (P<0.001). Psychiatric illness was
associated with 0.7 and 1.2 point higher MSAS subscale scores, and intravenous (IV) drug use
was associated with 0.4 and 0.5 higher subscale scores (out of four).
Conclusion—Pain and other physical and psychological symptoms were common among
ambulatory HIV patients. Pain and symptoms were strongly associated with psychiatric illness and
IV drug use. Future investigation should evaluate interventions that include psychiatric and
substance abuse components for HIV patients with pain.
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Introduction
Before combination antiretroviral therapy (ART), pain and physical and psychological
symptoms in patients with HIV were common [1–7], often missed by providers [3, 8], and
undertreated when found [9].
More effective ART has resulted in fewer opportunistic infections, and ART regimens with
fewer side effects are now standard initial therapy [10]. Also, current recommendations are
to initiate therapy at CD4+ cell counts of 500 cells/mm3, and perhaps even higher [11]. As a
result, HIV has become a chronic disease, with a near normal life expectancy [12]. Yet, HIV
patients face complications resulting from effects of therapy or disease, including
cardiometabolic abnormalities [13], frailty [14], neurocognitive impairment [15, 16], and
increased risk of malignancies [17–19]. At this new stage in the HIV epidemic, it is
important to investigate whether pain and symptoms have changed along with changes in the
trajectory of HIV disease.
The aims of this study were to determine the prevalence and severity of pain and other
symptoms experienced in an ambulatory population of HIV patients, to investigate risk
factors that may be related to pain and symptoms in this population, and to determine
whether patients’ pain and symptoms were recognized and treated by providers.
Methods
Study Population
Patients were recruited from the University of Pennsylvania’s Center for AIDS Research
(CFAR) Clinical Core Cohort. The CFAR cohort includes 2981 patients. They were seen by
CFAR staff every six months for five years, and then annually for five years, at which time
laboratory, demographic, and other survey-based data were collected.
For our study, patients were excluded if they had neurologic or cognitive impairments
rendering them incapable of completing the survey or providing informed consent. Between
October 2009 and January 2010, eligible patients were approached after their clinic visits
and interviewed by study staff not responsible for their clinical care. Patients who were
eligible but did not stay for the interview, such as patients not referred by their provider or
patients who declined to be interviewed, were not consented for the study. No data from this
group are available. However, data from the overall CFAR cohort were gathered for the
purposes of comparison to our study group.
The study was approved by the University of Pennsylvania Health System Institutional
Review Board, and all patients provided written informed consent.
Measures
We assessed pain using the Brief Pain Inventory-Short Form (BPI), a validated tool that has
been used to assess cancer and non-cancer pain, including that from HIV [7, 20]. The BPI
asks patients whether they have had pain other than “everyday” kinds of pain during the last
day. Patients with pain were asked to rate their pain on a scale of 0 to 10, at its worst, least,
average, and right now. Patients also reported the medications they have received for pain,
and relief provided on a scale of 0% to 100%. Study staff categorized medications into
opioids, nonsteroidal anti-inflammatories, acetaminophen, and medications for neuropathic
pain.
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We assessed other physical and psychological symptoms using the Memorial Symptom
Assessment Scale Short Form (MSAS), which has been used in patients with and without
cancer, including those with HIV [21, 22]. The MSAS asks patients to report whether they
have had any of 26 physical symptoms and 6 psychological symptoms over the past week.
For each symptom, patients were asked either about distress (0=symptom not present,
0.8=not at all, 1.6=a little bit, 2.4=somewhat, 3.2=quite a bit, and 4.0=very much) or
frequency (0=symptom not present, 1=rarely, 2=occasionally, 3=frequently, and 4=almost
constantly). Mean symptom scores were calculated by averaging the distress or frequency
associated with each symptom. Based on prior studies, we defined high distress associated
with physical symptoms as quite a bit or very much, and high frequency associated with
psychological symptoms as frequently or almost constantly [21, 23].
The CFAR database was queried for multiple variables, including each patient’s age, most
recent CD4+ cell count, viral load, race, tobacco use, psychiatric history (whether a
psychologist, therapist, physician, or other clinician has ever told the patient that they were
depressed, schizophrenic, or bipolar), and history of intravenous (IV) drug use (whether they
have ever injected any drugs). Viral load was further divided into viral load less than 75
copies/mL, the therapeutic goal of ART, and viral load less than 1000 copies/ml. “Blips” up
to 1000 copies/mL are unlikely to be clinically significant [24].
A chart review was performed to determine whether pain was mentioned anywhere in the
progress from the day of the interview. Trained reviewers used standardized forms to
systematically review charts. Reviewers were blinded to the questionnaire results for the
patients whose charts they reviewed.
Based on work regarding pain severity clustering using the BPI [25], we categorized pain as
mild (1–4), moderate (5–6), or severe (7–10). Patients rated the amount pain interferes with
their lives on a scale of 0 to 10, with regard to general activity, mood, walking ability, work,
relations with other people, sleep, and enjoyment of life. A patient’s overall pain
interference was calculated by averaging these domains of interference. The proportions of
patients with moderate to severe pain interference were determined using the same cutoffs as
above.
Analysis
Dichotomous variables were compared using Chi-squared and Fisher’s exact tests, and
continuous variables were compared using t-tests and the Wilcoxon rank sum test. Tests of
trend were assessed with the Cochran-Armitage Test of Trend for dichotomous variables
and the Jonckheere-Terpstra test for continuous variables.
Multivariable analyses assessing risk factors for presence of pain were performed using
logistic regression. Multivariable analyses assessing risk factors for MSAS subscale scores
as continuous variables (0–4) (physical symptom subscale or MSAS-PHYS, psychological
symptom subscale or MSAS-PSYCH, total MSAS score or TMSAS, and global distress
index or GDI) were performed using linear regression [26]. Risk factors assessed included
psychiatric illness, IV drug use history, tobacco use, race, CD4 category, and low viral load
(viral load < 1000 copies/ml). In all models, risk factors associated with the primary
outcome variable with a P<0.05 were assessed as primary variables. Potential confounders
included all of the baseline characteristics and were retained in the models if they changed
the association of the primary variable and the outcome by more than 15%.
Because MSAS subscales are calculated for an individual patient by adding the distress
associated with distress-related symptoms to the frequency associated with frequency-
Merlin et al. Page 3
related symptoms [26], we considered distress and frequency to be measures of the
symptom’s severity and reported them together.
Data were analyzed using SAS v 9.2 (SAS Institute Inc., Cary, North Carolina).
Results
We enrolled 156 patients from three sites. Patients were mostly male, middle-aged, African
American, knew of their diagnosis of HIV infection for several years, and had high CD4+
cell counts and undetectable viral loads. Many patients had a history of psychiatric illness or
IV drug use. In comparison to the full CFAR cohort, patients in this study were less likely to
have a history of injection drug use or psychiatric illness, and more likely to have a history
of tobacco use, but otherwise were very similar (Table 1).
Seventy-six (48.7%) reported having pain other than “everyday aches and pains” in the past
day. Median pain was 6/10 “on average” (interquartile range [IQR] 3–7). Of patients with
pain, 39 (51.3%) were in moderate to severe pain during the interview. Overall median pain
interference was 4.6 on a scale of 0 to 10 (IQR 4.1–7.0), with 43 (57.3%) patients with pain
reporting moderate to severe overall interference.
Patients experienced a median number of eight physical and psychological symptoms during
the past week (IQR 5.0–14.5). The most prevalent physical symptoms other than pain were
lack of energy and numbness or tingling in the hands and feet (Table 2). These also were the
most common “high distress” physical symptoms. A substantial number of patients (61,
39.1%) experienced “high distress” from three or more physical symptoms. More than half
the cohort experienced four of the six psychological symptoms (worrying, feeling sad,
difficulty sleeping, feeling irritable). Nearly half of all patients (74, 47.7%) experienced
“high distress” or “high frequency” from at least one psychological symptom.
Fifty-six (73.7%) of the patients reporting pain took analgesic medications; 32 (42.1%) were
prescribed opioids. Patients reported a median of 50% relief of pain after taking medication
(IQR 10%-80%). Of the 76 patients who reported pain, pain was documented in 51 (67.0%)
of the provider notes on that day. Providers were more likely to document pain of higher
severity; mild pain was documented in 14 (50.0%), moderate pain in 16 (76.2%), and severe
pain in 21 (80.8%) (P=0.007, Cochran-Armitage test of trend). As pain severity increased,
there was a trend toward more pain medication use, although it did not reach statistical
significance; 18 (64.3%) patients with mild pain took pain medication, as compared to 17
(77.3%) patients with moderate pain and 21 (80.8%) patients with severe pain (P=0.08,
Cochran-Armitage test of trend). Patients with severe pain were more likely to take opioids
(18/26, 69.2%) than patients with moderate (8, 36.4%) or mild pain (6, 21.4%) (P=0.001,
Cochran-Armitage test of trend).
Risk Factors for Pain
Patients with a history of IV drug use who had pain were more likely to have severe (6,
60%) or moderate (4, 40%) pain than patients without a history of IV drug use (P=0.005,
Cochran-Armitage test of trend). Also, patients with more psychological symptoms were
more likely to report pain. The frequency of pain in patients with one symptom was 31.8%,
two symptoms 42.1%, three symptoms 38.9%, four symptoms 58.3%, five symptoms
63.6%, and six symptoms 85.2% (P=0.0016, Cochrane-Armitage test of trend). None of the
other factors were associated with pain in univariate analyses. Thirty-seven (71.2%) patients
with psychiatric illness had pain, compared to 39 (37.9%) without psychiatric illness
(P=0.0002, Chi-square). In multivariable analyses, pain was 39.8% more common in
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patients with a history of psychiatric illness (P<0.001) and there were no confounders of this
association.
Risk Factors for Symptoms
Psychiatric illness was associated with a 0.7 point higher MSAS-PHYS subscale score
(P<0.001), and IV drug use was associated with a 0.5 higher MSAS-PHYS subscale score
(P<0.0005). There was no confounding of this association in the multivariable models. Low
viral load was associated with higher MSAS-PHYS (P=0.04); however, in the multivariable
model, the relationship between low viral load and MSAS-PHYS was no longer statistically
significant (P=0.06), and was associated with a change from 0.32 points on the MSAS-
PHYS subscale to 0.27.
Having a diagnosis of a psychiatric illness was associated with a 1.2 point higher MSAS-
PSYCH subscale score (P<0.001). There was no confounding in multivariable models.
Having a diagnosis of a psychiatric illness also was associated with a 0.7 point higher T-
MSAS subscale score (P<0.0001), and IV drug use was associated with a 0.4 point higher T-
MSAS subscale score (P<0.006). There was no confounding of these relations.
Psychiatric illness was associated with a 1.0 point higher GDI subscale score (P<0.0001),
and IV drug use was associated with a 0.5 point higher GDI subscale score (P<0.02). No
confounding was identified. Low viral load was associated with a higher GDI (P=0.04) but
the relationship between viral load and GDI was no longer statistically significant when
psychiatric illness was included as a confounder (P=0.07), and was associated with a change
from 0.4 points on the GDI subscale to 0.3.
Discussion
There have been several studies of pain and symptoms in the current HIV treatment era.
These studies established that pain and symptoms are still common [27–31], and suggested
weak relationships between pain and symptoms and sleep disturbances, fatigue, and ever
having AIDS. The relationship between pain and symptoms and CD4 count and race is less
clear [21, 32, 33].
Our results confirm that pain and symptoms are still prevalent and cause a significant
amount of distress and interference. We found that although providers documented moderate
to severe pain, patients reported only modest relief from pain medications. Studies from the
early treatment era suggest that providers often underestimate pain in patients with HIV [3].
Barriers to pain management, as identified in prior studies, are patient-related, such as
patients’ fear of addiction and medication side effects [34], and provider-related, such as
providers’ fear of addiction, lack of knowledge about pain management, and lack of access
to pain management experts [35]. Other potential barriers to adequate pain management
include inappropriately low doses or frequency of prescribed opioids, inadequate adherence,
or the pain being psychological and, therefore, unresponsive to opioid therapy. Regardless,
this study suggests that despite attempts at pharmacologic management, pain in this group of
ambulatory HIV patients is not under good control. This is a serious issue that merits
attention.
This is the first study in the current treatment era to suggest a strong relationship between
pain and symptoms and psychiatric illness and IV drug use. In this study, patients with
psychiatric illness were 40% more likely to have pain. Both psychiatric illness and IV drug
use were associated with higher MSAS-PHYS, TMSAS, and GDI subscales, ranging from
0.4–1.2. Although there is no consensus about what constitutes a clinically significant
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difference in MSAS subscale scores, it is striking that psychiatric illness and IV drug use are
consistently related to these measures of symptom burden.
Psychiatric illness and IV drug use are common comorbidities in patients with HIV [36].
Some studies from before the current treatment era suggest that HIV infected patients with a
history of IV drug use have a higher prevalence of pain and increased symptom-related
distress [7, 20, 37]. The relationship of pain and symptoms to psychiatric history and IV
drug use shown in this study also is consistent with data from early in the current treatment
era [36].
Our study has a few important limitations. It was done at a single academic medical center,
which may limit its generalizability. It is possible that patients who had pain and symptoms
were more likely to participate in this study, causing overestimates of pain and symptoms.
Although the BPI does ask about location of pain, this is a difficult question to interpret, so
we were unable to include these results. Knowing the location of pain, and whether more
than one site of pain was present, would have given us more insight into the patient’s pain
experience.
Numerous studies have shown that management of symptoms of chronic HIV disease, such
as pain, fatigue, and insomnia, results in improved quality of life [7, 38–41]. There is also
evidence that symptom management improves virologic suppression and adherence [42, 43,
22]. Therefore, understanding risk factors for pain and symptoms is an important part of
improving outcomes in patients with HIV.
We propose that HIV providers systematically screen for pain and symptoms, just as they
routinely screen for other prevalent, treatable comorbid conditions. Given the association
between pain and symptoms and IV drug use and psychiatric illness in this study, these
comorbidities must be addressed when treating HIV-infected patients with pain. Future
research should focus on interventions that combine pain management with psychiatric and
substance abuse treatment.
As urgent mortality issues in the management of chronic HIV disease wane, we believe that
the diagnosis and treatment of HIV patients’ pain and symptoms, with close attention to
psychiatric and IV drug use comorbidities, should be a part of routine HIV care.
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Table 1
Characteristics of Participants and Target Population
Characteristics Study Sample,
n=156
CFAR Cohort, n=2981
Median age (range) 47.5 (21–71) 50 (19–95)
Female gender (%) 43 (27.7%) 682 (22.9%)
Median years since diagnosis (range) 11 (0–25) 14 (0–28)
Median CD4 count (range) 497.5 (7.0–1512.0) 438.5 (0–2058.0)
CD4+ cell count category (%), cells/mm3
<50 7 (4.5%) 187 (6.5%)
50–199 12 (7.7%) 394 (13.7%)
200–499 56 (35.9%) 1131 (39.3%)
≥500 81 (51.9%) 1114 (38.7%)
VL < 75 copies/ml (%) 125 (80.6%) 1313 (44.0%)
VL < 1000 copies/ml (%) 136 (87.7%) 1629 (54.6%)
African-American (%) 90 (58.4%) 1798 (60.3%)
History of Intravenous Drug Use (%) 15 (9.9%) 622 (21.5%)a
History of Psychiatric Illness (%) 52 (33.5%) 715 (48.2%)b
History of Tobacco Use (%) 104 (67.5%) 1282 (45.6%)c
a
n=2891 because of missing data.
b
n=1484 because of missing data; questions regarding psychiatric illness were introduced in a later version of the CFAR study questionnaire.
c
n=2809 because of missing data; questions regarding tobacco use were introduced into a later version of the CFAR study questionnaire.
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Table 2
Memorial Symptom Assessment Scale Results by Symptom
Symptom Prevalence
n (%)
Mean
Symptom
Score ± SD
High Distress or f
Frequency
n (%)a
Physical Symptoms
Pain 96 (61.9) 1.5 ± 1.5 48 (31.0)
Lack of energy 89 (57.1) 1.2 ± 1.4 30 (19.2)
Numbness/tingling in hands and feet 72 (46.2) 1.0 ±1.4 29 (18.6)
Feeling drowsy 58 (37.2) 0.7 ± 1.2 17 (10.9)
Sweats 53 (34.0) 0.6 ± 1.2 15 (9.6)
Cough 52 (33.3) 0.6 ± 1.1 16 (10.3)
Dry mouth 51 (32.7) 0.6 ± 1.1 14 (9.0)
Diarrhea 49 (31.4) 0.7 ± 1.2 21 (13.5)
“I don’t look like myself” 42 (27.1) 0.6 ± 1.3 21 (13.5)
Feeling bloated 39 (25.2) 0.5 ± 1.1 15 (9.7)
Shortness of breath 39 (25.0) 0.5 ± 1.1 14 (9.0)
Itching 37 (23.7) 0.5 ± 1.2 16 (10.3)
Lack of appetite 36 (23.1) 0.4 ± 1.0 10 (6.4)
Problems with sexual interest or activity 35 (22.6) 0.6 ± 1.2 20 (12.9)
Nausea 35 (22.4) 0.4 ± 0.9 11 (7.1)
Problems with urination 35 (22.4) 0.5 ± 1.1 15 (9.6)
Changes in skin 32 (20.5) 0.4 ± 1.1 13 (8.3)
Weight loss 28 (17.9) 0.3 ± 0.9 8 (5.1)
Dizziness 27 (17.3) 0.3 ± 0.8 8 (5.1)
Constipation 22 (14.1) 0.3 ± 0.8 5 (3.2)
Change in the way food tastes 19 (12.2) 0.2 ± 0.8 6 (3.8)
Hair loss 19 (12.2) 0.2 ± 0.8 6 (3.8)
Swelling of arms or legs 15 (9.6) 0.2 ± 0.7 6 (3.8)
Difficulty swallowing 13 (8.3) 0.1 ± 0.6 4 (2.6)
Vomiting 13 (8.3) 0.1 ± 0.5 4 (2.6)
Mouth Sores 12 (7.7) 0.1 ± 0.6 4 (2.6)
Psychological Symptoms
Worrying 98 (62.8) 1.5 ± 1.4 45 (28.8)
Feeling sad 86 (55.1) 1.1 ± 1.3 27 (17.3)
Difficulty sleeping 86 (55.1) 1.4 ± 1.5 45 (28.8)
Feeling irritable 82 (52.6) 1.1 ± 1.2 22 (14.1)
Feeling nervous 67 (42.9) 1.0 ± 1.3 21 (13.5)
Difficulty concentrating 63 (40.4) 0.8 ±1.3 20 (12.8)
a
Frequency reported for worrying, feeling sad, feeling irritable, and feeling nervous; distress reported for the remainder.
